Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,460
  • Shares Outstanding, K 1,728
  • Annual Sales, $ 570 K
  • Annual Income, $ -20,250 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.98
  • Price/Sales 11.05
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.56 +21.48%
on 10/21/24
4.81 -35.34%
on 10/31/24
+0.58 (+22.92%)
since 10/18/24
3-Month
1.39 +123.74%
on 10/08/24
6.00 -48.17%
on 09/17/24
-1.70 (-35.34%)
since 08/16/24
52-Week
1.39 +123.74%
on 10/08/24
13.02 -76.11%
on 02/15/24
-9.35 (-75.04%)
since 11/17/23

Most Recent Stories

More News
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities

Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...

VCNX : 3.11 (-1.58%)
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNX : 3.11 (-1.58%)
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNX : 3.11 (-1.58%)
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

VCNX : 3.11 (-1.58%)
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNX : 3.11 (-1.58%)
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

VCNX : 3.11 (-1.58%)
MarketBeat Week in Review – 2/6 - 2/10

Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely

AI : 26.54 (+2.12%)
BBAI : 1.7600 (+3.53%)
PLTR : 61.26 (-6.86%)
SOUN : 6.19 (-2.67%)
MSFT : 415.76 (+0.18%)
ON : 66.48 (+2.66%)
AAPL : 228.02 (+1.34%)
AMZN : 201.70 (-0.45%)
TTWO : 182.93 (+2.99%)
MRK : 96.56 (+0.26%)
VCNX : 3.11 (-1.58%)
ENPH : 62.40 (+4.84%)
Should Investors Buy or Sell the Vaccinex Patent News?

Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?

VCNX : 3.11 (-1.58%)
MRK : 96.56 (+0.26%)
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other...

VCNX : 3.11 (-1.58%)
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease

ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated...

VCNX : 3.11 (-1.58%)

Business Summary

Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of...

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.48
1st Resistance Point 3.30
Last Price 3.11
1st Support Level 2.99
2nd Support Level 2.86
3rd Support Level 2.68

See More

52-Week High 13.02
Fibonacci 61.8% 8.58
Fibonacci 50% 7.21
Fibonacci 38.2% 5.83
Last Price 3.11
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar